Stockscreener 앱 받기
16.66
0.77%
-0.13
시간 외 거래:
16.66
전일 마감가:
$16.79
열려 있는:
$16.86
하루 거래량:
1.33M
Relative Volume:
0.38
시가총액:
$821.47M
수익:
순이익/손실:
$-166.31M
주가수익비율:
-3.7353
EPS:
-4.4602
순현금흐름:
$-160.59M
1주 성능:
-0.42%
1개월 성능:
-39.75%
6개월 성능:
-43.74%
1년 성능:
-15.11%
1일 변동 폭
$16.48
$17.23
1주일 범위
$15.26
$17.23
52주 변동 폭
$11.36
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
명칭
Arrivent Biopharma Inc
전화
240-780-6356
주소
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
16.66 | 821.47M | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2025-12-10 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 개시 | Truist | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-03-20 | 개시 | B. Riley Securities | Buy |
| 2025-03-10 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2024-02-20 | 개시 | Citigroup | Buy |
| 2024-02-20 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | Jefferies | Buy |
모두보기
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history - Yahoo Finance Singapore
Form 13D/A ArriVent BioPharma For: 8 October By Investing.com - Investing.com India
Form 13D/A ArriVent BioPharma For: 8 October By Investing.com - Investing.com Canada
BTIG cuts ArriVent BioPharma stock price target on trial results - Investing.com
Chinese biotech faces reality check as ArriVent drug failure sinks stock in US - South China Morning Post
Avbp stock hits 52-week low at 12.09 USD - Investing.com
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) - PR Newswire
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low - AOL.com
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings - Benzinga
Why ArriVent BioPharma (AVBP) Stock Is Down Today - Quiver Quantitative
Why ArriVent BioPharma (AVBP) Stock Is Down Today - Quiver Quantitative
There are notable gap-ups and gap-downs in today's session. - ChartMill
ArriVent stock plunges on cancer trial failure (AVBP:NASDAQ) - Seeking Alpha
AVBP Stock Holds Range As Cash-Rich Biotech Plans Next Move - Timothy Sykes
AVBP Stock Holds Range As Cash-Rich Biotech Plans Next Move - Timothy Sykes
AVBP Slips 2.28% as ArriVent BioPharma Tests Support Near $26.86Runaway Gap - https://www.siam.in/
AVBP Slips 2.28% as ArriVent BioPharma Tests Support Near $26.86Volatility Breakout Picks - https://www.dars.gov.et/
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study - TipRanks
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP) - Seeking Alpha
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - qz.com
Why Did ArriVent BioPharma (AVBP) Move Today? - Simply Wall Street
Why Did ArriVent BioPharma (AVBP) Move Today? - sahmcapital.com
ArriVent (AVBP) Trading: Posts a 2.95% Loss to $28.26 in the Current Update; Levels: Price Remains Between $26.85 Support and $29.67 ResistanceIV Spike - vinanet.vn
109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd. - MarketBeat
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Moomoo
HC Wainwright Issues Pessimistic Forecast for AVBP Earnings - MarketBeat
What is HC Wainwright's Estimate for AVBP FY2027 Earnings? - MarketBeat
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47 - Moomoo
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal - Sahm
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook - Investing.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - MarketBeat
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook By Investing.com - Investing.com Canada
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash - MyChesCo
ArriVent Biopharma price target lowered to $40 from $43 at Citi - TipRanks
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Technical Reactions to AVBP Trends in Macro Strategies - Stock Traders Daily
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50 - Moomoo
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC - AllSci
ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - MarketBeat
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks
ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
ArriVent inks China partnership for ARR-002 development - TipRanks
Arrivent Biopharma Inc (AVBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.28%
자본화:
|
볼륨(24시간):